Symposium: Vaporised nicotine products for smoking cessation amongst people receiving drug and alcohol treatment or those with comorbidities

Billie Bonevski; Natalie Walker; Chris Bullen; Coral Gartner; Victoria  Manning; Eliza Skelton; George Laking

doi:10.1111/dar.12862

Abstract

Aim of Abstract: Among people in drug and alcohol (AOD) treatment, with mental health issues and/or living with hepatitis C (HCV) or HIV, smoking rates continue to be substantially higher than the general community. Many factors related to addiction, lack of cessation support and high levels of smoking in their social network contribute to high relapse rates back to smoking in these populations.
New ways of thinking about how to address smoking amongst these populations are needed. The aim of this 75 minutes symposium is to highlight a number of current trials in Australia and New Zealand of vaporised nicotine products (VNPs or e-cigarettes) for smoking cessation in the drug and alcohol treatment setting or for people with comorbidities. A discussion with attendees will be facilitated considering a number of issues related to the use of VNPs in the drug and alcohol setting, including perceived safety, effectiveness, challenges, opportunities and Indigenous populations.

Original language	English
Article number	Paper 54
Pages (from-to)	s5-s5
Number of pages	1
Journal	Drug and Alcohol Review
Volume	37
Issue number	s3
DOIs	https://doi.org/10.1111/dar.12862
Publication status	Published - Nov 2018
Externally published	Yes
Event	2018 Australasian Professional Society on Alcohol and other Drugs Conference - Auckland, New Zealand Duration: 4 Nov 2018 → 7 Nov 2018

Keywords

Conference abstract
Conference symposium
Vaporised nicotine products
E-cigarettes
drug and alcohol (AOD) treatment
Indigenous Australians
Indigenous populations

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/dar.12862Licence: In Copyright

Cite this

@article{eae0b83f4a894218928ddbc013204dcc,

title = "Symposium: Vaporised nicotine products for smoking cessation amongst people receiving drug and alcohol treatment or those with comorbidities",

abstract = "Aim of Abstract: Among people in drug and alcohol (AOD) treatment, with mental health issues and/or living with hepatitis C (HCV) or HIV, smoking rates continue to be substantially higher than the general community. Many factors related to addiction, lack of cessation support and high levels of smoking in their social network contribute to high relapse rates back to smoking in these populations.New ways of thinking about how to address smoking amongst these populations are needed. The aim of this 75 minutes symposium is to highlight a number of current trials in Australia and New Zealand of vaporised nicotine products (VNPs or e-cigarettes) for smoking cessation in the drug and alcohol treatment setting or for people with comorbidities. A discussion with attendees will be facilitated considering a number of issues related to the use of VNPs in the drug and alcohol setting, including perceived safety, effectiveness, challenges, opportunities and Indigenous populations.",

keywords = "Conference abstract, Conference symposium, Vaporised nicotine products, E-cigarettes, drug and alcohol (AOD) treatment, Indigenous Australians, Indigenous populations",

author = "Billie Bonevski and Natalie Walker and Chris Bullen and Coral Gartner and Victoria Manning and Eliza Skelton and George Laking",

year = "2018",

month = nov,

doi = "10.1111/dar.12862",

language = "English",

volume = "37",

pages = "s5--s5",

journal = "Drug and Alcohol Review",

issn = "0959-5236",

publisher = "Carfax Publishing Co",

number = "s3",

note = "2018 Australasian Professional Society on Alcohol and other Drugs Conference, APSAD 2018 ; Conference date: 04-11-2018 Through 07-11-2018",

}

TY - JOUR

T1 - Symposium

T2 - 2018 Australasian Professional Society on Alcohol and other Drugs Conference

AU - Bonevski, Billie

AU - Walker, Natalie

AU - Bullen, Chris

AU - Gartner, Coral

AU - Manning, Victoria

AU - Skelton, Eliza

AU - Laking, George

PY - 2018/11

Y1 - 2018/11

N2 - Aim of Abstract: Among people in drug and alcohol (AOD) treatment, with mental health issues and/or living with hepatitis C (HCV) or HIV, smoking rates continue to be substantially higher than the general community. Many factors related to addiction, lack of cessation support and high levels of smoking in their social network contribute to high relapse rates back to smoking in these populations.New ways of thinking about how to address smoking amongst these populations are needed. The aim of this 75 minutes symposium is to highlight a number of current trials in Australia and New Zealand of vaporised nicotine products (VNPs or e-cigarettes) for smoking cessation in the drug and alcohol treatment setting or for people with comorbidities. A discussion with attendees will be facilitated considering a number of issues related to the use of VNPs in the drug and alcohol setting, including perceived safety, effectiveness, challenges, opportunities and Indigenous populations.

AB - Aim of Abstract: Among people in drug and alcohol (AOD) treatment, with mental health issues and/or living with hepatitis C (HCV) or HIV, smoking rates continue to be substantially higher than the general community. Many factors related to addiction, lack of cessation support and high levels of smoking in their social network contribute to high relapse rates back to smoking in these populations.New ways of thinking about how to address smoking amongst these populations are needed. The aim of this 75 minutes symposium is to highlight a number of current trials in Australia and New Zealand of vaporised nicotine products (VNPs or e-cigarettes) for smoking cessation in the drug and alcohol treatment setting or for people with comorbidities. A discussion with attendees will be facilitated considering a number of issues related to the use of VNPs in the drug and alcohol setting, including perceived safety, effectiveness, challenges, opportunities and Indigenous populations.

KW - Conference abstract

KW - Conference symposium

KW - Vaporised nicotine products

KW - E-cigarettes

KW - drug and alcohol (AOD) treatment

KW - Indigenous Australians

KW - Indigenous populations

UR - https://apsadconference2021.com.au/abstract-submissions/

U2 - 10.1111/dar.12862

DO - 10.1111/dar.12862

M3 - Meeting Abstract

SN - 0959-5236

VL - 37

SP - s5-s5

JO - Drug and Alcohol Review

JF - Drug and Alcohol Review

IS - s3

M1 - Paper 54

Y2 - 4 November 2018 through 7 November 2018

ER -